Pelacarsen reduces the need for lipoprotein apheresis in patients with elevated lipoprotein(a) and cardiovascular disease: The Phase 3 Lp(a)FRONTIERS APHERESIS trial
Event:
ESC Congress 2025
Topic:
Lipid-Lowering Agents
Session:
Cardiotoxicity and protection: from bench to bedside